BioScience Managers
As an international healthcare investment firm that finances and enables innovative science and technology with the potential to transform healthcare, we have a team with the ambition and experience to deliver impressive investment returns.
Latest news
- Acrux (ASX:ACR) pushes ahead with $2M SPP 10 January 2021
- NICE Publishes Briefing on Saluda’s Evoke Closed-Loop Spinal Cord Stimulation (SCS) System 22 December 2020
- Destiny Pharma Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections 22 December 2020